TY - JOUR
T1 - Erratum
T2 - Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod (Neurol Neuroimmunol Neuroinflamm (2022) 9: 4 (e1178) DOI: 10.1212/NXI.0000000000001178)
AU - Palomares Cabeza, V.
AU - Kummer, L. Y. L.
AU - Wieske, L.
PY - 2022/11/26
Y1 - 2022/11/26
N2 - In the Clinical/Scientific Note "Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod"by Palomares Cabeza et al.,1 the final name in Appendix 2 should be listed as "C.A.C.M. van Els."The authors regret the error.
AB - In the Clinical/Scientific Note "Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod"by Palomares Cabeza et al.,1 the final name in Appendix 2 should be listed as "C.A.C.M. van Els."The authors regret the error.
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85161964703&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/36028312
U2 - https://doi.org/10.1212/NXI.0000000000200036
DO - https://doi.org/10.1212/NXI.0000000000200036
M3 - Erratum/Corrigendum
C2 - 36028312
SN - 2332-7812
VL - 9
JO - Neurology® neuroimmunology & neuroinflammation
JF - Neurology® neuroimmunology & neuroinflammation
IS - 6
M1 - e200036
ER -